Severe Acute Respiratory Syndrome (SARS) R&D Pipeline Analysis Report, Q4 2020
Severe Acute Respiratory Syndrome (SARS) Pipeline Overview
The Q4 Severe Acute Respiratory Syndrome (SARS) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Severe Acute Respiratory Syndrome (SARS), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Severe Acute Respiratory Syndrome (SARS) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Severe Acute Respiratory Syndrome (SARS) disease overview, Severe Acute Respiratory Syndrome (SARS) types, Severe Acute Respiratory Syndrome (SARS) symptoms, causes, and FDA/EMA approved treatment options.
Severe Acute Respiratory Syndrome (SARS) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Severe Acute Respiratory Syndrome (SARS) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Severe Acute Respiratory Syndrome (SARS) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 25 companies. Business profiles and contact details of the companies actively perusing Severe Acute Respiratory Syndrome (SARS) pipeline are assessed.
Severe Acute Respiratory Syndrome (SARS) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Severe Acute Respiratory Syndrome (SARS) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Severe Acute Respiratory Syndrome (SARS) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Severe Acute Respiratory Syndrome (SARS) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Severe Acute Respiratory Syndrome (SARS) Pipeline Market News and Developments during 2020
The Severe Acute Respiratory Syndrome (SARS) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Severe Acute Respiratory Syndrome (SARS) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Severe Acute Respiratory Syndrome (SARS) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Severe Acute Respiratory Syndrome (SARS), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Severe Acute Respiratory Syndrome (SARS) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Severe Acute Respiratory Syndrome (SARS) disease overview, Severe Acute Respiratory Syndrome (SARS) types, Severe Acute Respiratory Syndrome (SARS) symptoms, causes, and FDA/EMA approved treatment options.
Severe Acute Respiratory Syndrome (SARS) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Severe Acute Respiratory Syndrome (SARS) indication. The report presents near-term and long-term pipeline development trends and potential insights.
Severe Acute Respiratory Syndrome (SARS) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 25 companies. Business profiles and contact details of the companies actively perusing Severe Acute Respiratory Syndrome (SARS) pipeline are assessed.
Severe Acute Respiratory Syndrome (SARS) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Severe Acute Respiratory Syndrome (SARS) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Severe Acute Respiratory Syndrome (SARS) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Severe Acute Respiratory Syndrome (SARS) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Severe Acute Respiratory Syndrome (SARS) Pipeline Market News and Developments during 2020
The Severe Acute Respiratory Syndrome (SARS) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Severe Acute Respiratory Syndrome (SARS) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Severe Acute Respiratory Syndrome (SARS) pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 25 companies are included including Adagio Therapeutics Inc, AIkido Pharma Inc, AIM ImmunoTech Inc, Autoimmune Technologies LLC, Biotron Ltd, CEL-SCI Corp, Citospin SL, Cocrystal Pharma Inc, Fab’entech SA, Gilead Sciences Inc, Global BioLife Inc Ltd, Immodulon Therapeutics Ltd, Lattice Biologics Ltd, Merck & Co Inc, Novartis AG, Novavax Inc, Oncovir Inc, Organicell Regenerative Medicine Inc, Pharmazz Inc, Phelix Therapeutics LLC, Pulmotect Inc, Sagimet Biosciences, Sorrento Therapeutics Inc, Trimunocor Ltd, VBI Vaccines Inc,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Severe Acute Respiratory Syndrome (SARS) pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Severe Acute Respiratory Syndrome (SARS) Pipeline, 2020
2.2 Most focused Mechanism of Action in Severe Acute Respiratory Syndrome (SARS) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Severe Acute Respiratory Syndrome (SARS) pipeline
2.5 Active Companies Developing Severe Acute Respiratory Syndrome (SARS) pipeline
3. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Adagio Therapeutics Inc
AIkido Pharma Inc
AIM ImmunoTech Inc
Autoimmune Technologies LLC
Biotron Ltd
CEL-SCI Corp
Citospin SL
Cocrystal Pharma Inc
Fab’entech SA
Gilead Sciences Inc
Global BioLife Inc Ltd
Immodulon Therapeutics Ltd
Lattice Biologics Ltd
Merck & Co Inc
Novartis AG
Novavax Inc
Oncovir Inc
Organicell Regenerative Medicine Inc
Pharmazz Inc
Phelix Therapeutics LLC
Pulmotect Inc
Sagimet Biosciences
Sorrento Therapeutics Inc
Trimunocor Ltd
VBI Vaccines Inc
5. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Severe Acute Respiratory Syndrome (SARS) Pipeline, 2020
2.2 Most focused Mechanism of Action in Severe Acute Respiratory Syndrome (SARS) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Severe Acute Respiratory Syndrome (SARS) pipeline
2.5 Active Companies Developing Severe Acute Respiratory Syndrome (SARS) pipeline
3. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Adagio Therapeutics Inc
AIkido Pharma Inc
AIM ImmunoTech Inc
Autoimmune Technologies LLC
Biotron Ltd
CEL-SCI Corp
Citospin SL
Cocrystal Pharma Inc
Fab’entech SA
Gilead Sciences Inc
Global BioLife Inc Ltd
Immodulon Therapeutics Ltd
Lattice Biologics Ltd
Merck & Co Inc
Novartis AG
Novavax Inc
Oncovir Inc
Organicell Regenerative Medicine Inc
Pharmazz Inc
Phelix Therapeutics LLC
Pulmotect Inc
Sagimet Biosciences
Sorrento Therapeutics Inc
Trimunocor Ltd
VBI Vaccines Inc
5. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. SEVERE ACUTE RESPIRATORY SYNDROME (SARS) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
